ClinicalTrials.gg
CompletedNCT01353703Updated Jan 2, 2020Results posted

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

A Phase 3 interventional study of Infanrix hexa™ in Poliomyelitis, Tetanus and Acellular Pertussis, sponsored by GlaxoSmithKline. Completed at 4 sites in India. Open to participants aged 6 Weeks to 10 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
6 Weeks to 10 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Poliomyelitis.

Enrollment
12th of 14
224 · median 467
Started
2012
the only one that year
Phase 3
7 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
13 of 14
GlaxoSmithKline

Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, this one is the 12th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 7th registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

None of the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis is open now. The open studies under Poliomyelitis, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 6 Weeks to 10 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis as a file.
02

Study summary

This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-HBV-IPV/Hib) when administered as a primary vaccination course to Indian infants according to a 6-10-14 weeks or a 2-4-6 months schedule.

03

Conditions studied

  • Poliomyelitis
  • Tetanus
  • Acellular Pertussis
  • Haemophilus Influenzae Type b
  • Diphtheria
  • Hepatitis B
  • Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Keywords

  • Infanrix hexa™
  • Primary vaccination
  • India
  • combination vaccine
  • infants
04

Who can participate

Ages eligible
6 Weeks to 10 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must satisfy ALL the following criteria at study entry:

  • A male or female between, and including, 6 and 10 weeks of age at the time of the first vaccination
  • Documented administration of a vaccine dose at birth
  • Subjects who the investigator believes that their parent(s)/legally acceptable representative(s) [LAR(s)] can and will comply with the requirements of the protocol
  • Written obtained from the parent(s)/LAR(s) of the subject
  • Healthy subjects as established by medical history and clinical examination before entering into the study
  • Born after a gestation period of at least 36 weeks

Exclusion criteria

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If ANYexclusion criterion applies, the subject must not be included in the study:

  • Child in care
  • Use of any or non-registered product other than the study vaccines within 30 days preceding the first dose, or planned use during the study period
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose
  • Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, or planned administration during the study period, with the exception of oral human rotavirus (HRV) vaccination which is allowed at any time during the study
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
  • Evidence of previous diphtheria, tetanus, pertussis, , poliomyelitis and Haemophilus influenzae type b (Hib) vaccination or disease, with the exception of a birth dose of hepatitis B vaccine and oral poliovirus vaccine (OPV) as per local standard of care
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
  • Family history of congenital or hereditary immunodeficiency
  • History of any reaction or likely to be exacerbated by any component of the vaccine
  • Major congenital defects or serious chronic illness
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period
  • Acute disease and/or fever at the time of enrolment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    INFANRIX HEXA 6-10-14 GROUP

    Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.

    Biological: Infanrix hexa™

  • Active comparator
    INFANRIX HEXA 2-4-6 GROUP

    Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.

    Biological: Infanrix hexa™

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens

    A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  2. Number of Seroprotected Subjects Against Hepatitis B (HBs)

    A seroprotected subject was defined as a vaccinated subject with anti-HBS antibody concentration ≥ 10 milli-international units per milliliter (mIU/mL).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  3. Number of Seroprotected Subjects Against Poliovirus (Polio) Types 1,2,3 Antigens

    A seroprotected subject was defined as a subject with anti-Poliovirus 1,2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  4. Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (PRP) Antigens

    A seroprotected subject was defined as a subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  5. Number of Subjects With Vaccine Response for Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)

    Vaccine response was defined as : For initially seronegative subjects (S-), antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at 1 month after the third dose; For initially seropositive subjects (S+): antibody concentration at 1 month after the third dose ≥ 1 fold increase in the pre-vaccination antibody concentration.

    Time frame: One month post Dose 3 (Month 3 or Month 5)

Secondary outcomes

  1. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  2. Anti-HBs Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  3. Anti-Polio Types 1, 2, 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs).

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  4. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  5. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  6. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

    A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

    Time frame: One month post Dose 3 (Month 3 or Month 5)

  7. Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 Antigens

    A seroprotected subject was defined as a subject with anti-Polio type 1, 2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).

    Time frame: At Month 0

  8. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

    A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

    Time frame: At Month 0

  9. Number of Seroprotected Subjects Against Anti-HBs Antigens

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

    Time frame: At Month 0

  10. Anti-Polio Types 1, 2 and 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs).

    Time frame: At Month 0

  11. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

    Time frame: At Month 0

  12. Anti-HBs Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

    Time frame: At Month 0

  13. Number of Subjects With Any Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of any particular symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) post-vaccination period after each dose and across doses: Up to Month 2 (Infanrix Hexa 6-10-14 Group) or Month 4 (Infanrix Hexa 2-4-6 Group)

  14. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = incidence of any particular symptom regardless of intensity grade or relationship to study vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period after each dose and across doses: Up to Month 2 (Infanrix Hexa 6-10-14 Group) or Month 4 (Infanrix Hexa 2-4-6 Group)

  15. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day (Days 0-30) post-vaccination period: Up to Month 3 (Infanrix Hexa 6-10-14 Group) or Month 5 (Infanrix Hexa 2-4-6 Group)

  16. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the entire study period (from Month 0 up to Month 3 (Infanrix Hexa 6-10-14 Group) or Month 5 (Infanrix Hexa 2-4-6 Group))

07

Results

Posted Jan 25, 2019

Participant flow

Participant flow — Overall Study
MilestoneInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Started112112
Completed111112
Not completed10
Withdrew: Migrated/moved from study area10

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens

A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-D105106
Anti-T105106
PrimaryNumber of Seroprotected Subjects Against Hepatitis B (HBs)

A seroprotected subject was defined as a vaccinated subject with anti-HBS antibody concentration ≥ 10 milli-international units per milliliter (mIU/mL).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Hepatitis B (HBs)
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Number of Seroprotected Subjects Against Hepatitis B (HBs)101104
PrimaryNumber of Seroprotected Subjects Against Poliovirus (Polio) Types 1,2,3 Antigens

A seroprotected subject was defined as a subject with anti-Poliovirus 1,2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Poliovirus (Polio) Types 1,2,3 Antigens
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-Polio 19999
Anti-Polio 27788
Anti-Polio 37379
PrimaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (PRP) Antigens

A seroprotected subject was defined as a subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (PRP) Antigens
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (PRP) Antigens104105
PrimaryNumber of Subjects With Vaccine Response for Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)

Vaccine response was defined as : For initially seronegative subjects (S-), antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at 1 month after the third dose; For initially seropositive subjects (S+): antibody concentration at 1 month after the third dose ≥ 1 fold increase in the pre-vaccination antibody concentration.

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Response for Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-PT, S-6167
Anti-PT, S+4436
Anti-FHA, S-1212
Anti-FHA, S+8688
Anti-PRN, S-8689
Anti-PRN, S+1814
SecondaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-D2.334 (2.049 to 2.659)3.726 (3.26 to 4.258)
Anti-T3.307 (2.925 to 3.739)4.904 (4.378 to 5.493)
SecondaryAnti-HBs Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-HBs Antibody Concentrations1695.7 (1395.2 to 2060.9)3314.5 (2645.2 to 4153.1)
SecondaryAnti-Polio Types 1, 2, 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Geometric mean · Titers
Anti-Polio Types 1, 2, 3 Antibody Titers
TitersInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-Polio 1884.3 (666.6 to 1173.1)1799.2 (1429 to 2265.5)
Anti-Polio 2840.2 (616.9 to 1144.2)2138.7 (1658.1 to 2758.7)
Anti-Polio 3923.7 (691.9 to 1233.2)2245.5 (1866.1 to 2702.1)
SecondaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-PRP Antibody Concentrations2.697 (2.176 to 3.343)5.404 (4.168 to 7.006)
SecondaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-PT107.3 (96.6 to 119.1)108.2 (97.4 to 120.2)
Anti-FHA293.7 (259.4 to 332.6)369.3 (335.5 to 406.5)
Anti-PRN224.4 (194.2 to 259.3)243.6 (213.2 to 278.4)
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

Time frame:
One month post Dose 3 (Month 3 or Month 5)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-PT105106
Anti-FHA105106
Anti-PRN105106
SecondaryNumber of Seroprotected Subjects Against Polio Type 1, 2 and 3 Antigens

A seroprotected subject was defined as a subject with anti-Polio type 1, 2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).

Time frame:
At Month 0
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 Antigens
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-Polio 17170
Anti-Polio 23842
Anti-Polio 32330
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

Time frame:
At Month 0
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-PT4437
Anti-FHA8990
Anti-PRN1915
SecondaryNumber of Seroprotected Subjects Against Anti-HBs Antigens

A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

Time frame:
At Month 0
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-HBs Antigens
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Number of Seroprotected Subjects Against Anti-HBs Antigens1413
SecondaryAnti-Polio Types 1, 2 and 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame:
At Month 0
Reported as:
Geometric mean · Titers
Anti-Polio Types 1, 2 and 3 Antibody Titers
TitersInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-Polio 153.5 (33.5 to 85.3)31.9 (21.5 to 47.2)
Anti-Polio 232.5 (19.2 to 55)36.2 (22.2 to 59)
Anti-Polio 38 (5.9 to 10.8)11.9 (8.3 to 17)
SecondaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

Time frame:
At Month 0
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-PT5 (4.2 to 6)4.6 (3.8 to 5.6)
Anti-FHA18.7 (15 to 23.3)20.1 (16.1 to 25.2)
Anti-PRN3.4 (2.9 to 3.9)3.2 (2.8 to 3.7)
SecondaryAnti-HBs Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

Time frame:
At Month 0
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Anti-HBs Antibody Concentrations5.9 (4.2 to 8.3)5.6 (4.1 to 7.7)
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of any particular symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) post-vaccination period after each dose and across doses: Up to Month 2 (Infanrix Hexa 6-10-14 Group) or Month 4 (Infanrix Hexa 2-4-6 Group)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Any Pain, Dose 12311
Any Redness, Dose 131
Any Swelling, Dose 174
Any Pain, Dose 2133
Any Redness, Dose 201
Any Swelling, Dose 222
Any Pain, Dose 3106
Any Redness, Dose 330
Any Swelling, Dose 323
Any Pain, Across doses2815
Any Swelling, Across doses62
Any Redness, Across doses89
SecondaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = incidence of any particular symptom regardless of intensity grade or relationship to study vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period after each dose and across doses: Up to Month 2 (Infanrix Hexa 6-10-14 Group) or Month 4 (Infanrix Hexa 2-4-6 Group)
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Any Drowsiness, Dose 102
Any Irritability/fussiness, Dose 185
Any Loss of appetite, Dose 113
Any Temperature/(Axillary), Dose 1107
Any Drowsiness, Dose 200
Any Irritability/fussiness, Dose 225
Any Loss of appetite, Dose 201
Any Temperature/(Axillary), Dose 257
Any Drowsiness, Dose 300
Any Irritability/fussiness, Dose 333
Any Loss of appetite, Dose 311
Any Temperature/(Axillary), Dose 336
Any Drowsiness, Across doses02
Any Irritability/fussiness, Across doses1310
Any Loss of appetite, Across doses25
Any Temperature/(Axillary), Across doses1717
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day (Days 0-30) post-vaccination period: Up to Month 3 (Infanrix Hexa 6-10-14 Group) or Month 5 (Infanrix Hexa 2-4-6 Group)
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Number of Subjects With Unsolicited Adverse Events (AEs)4025
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the entire study period (from Month 0 up to Month 3 (Infanrix Hexa 6-10-14 Group) or Month 5 (Infanrix Hexa 2-4-6 Group))
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Number of Subjects With Serious Adverse Events (SAEs)23

Adverse events

Collected over Solicited symptoms: during the 4-day (Days 0-3) post-vaccination period. Unsolicited AEs: during the 31-day (Days 0-30) post-vaccination period. SAEs: during the entire study period (from Month 0 to Month 3 or Month 5).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix Hexa 6-10-14 Group0/112 (0%)2/112 (1.8%)45/112 (40.2%)
Infanrix Hexa 2-4-6 Group0/112 (0%)3/112 (2.7%)36/112 (32.1%)
Most frequent serious events
Most frequent serious events
EventInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
Lower respiratory tract infectionInfections and infestations0/1122/112
BronchiolitisInfections and infestations1/1120/112
PneumoniaInfections and infestations1/1121/112
Most frequent other events
Most frequent other events
EventInfanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 Group
PainGeneral disorders28/11215/112
PyrexiaGeneral disorders18/11217/112
Upper respiratory tract infectionInfections and infestations18/11211/112
IrritabilityPsychiatric disorders13/11210/112
SwellingGeneral disorders8/1129/112
ErythemaSkin and subcutaneous tissue disorders6/1122/112
RhinitisInfections and infestations4/1126/112

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Infanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 GroupTotal
Mean6.7 ± 1.046.8 ± 1.136.75 ± 1.08
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 GroupTotal
Female5252104
Male6060120
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Infanrix Hexa 6-10-14 GroupInfanrix Hexa 2-4-6 GroupTotal
Asian-Central/South Asian heritage112112224
08

Study locations

4 sites
  • GSK Investigational Site
    Belgaun, 590010, India
  • GSK Investigational Site
    Chennai, India
  • GSK Investigational Site
    Pune, 411018, India
  • GSK Investigational Site
    Pune, India
09

References and documents

Publications

  • Lalwani SK, Agarkhedkar S, Sundaram B, Mahantashetti NS, Malshe N, Agarkhedkar S, Van Der Meeren O, Mehta S, Karkada N, Han HH, Mesaros N. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants. Hum Vaccin Immunother. 2017 Jan 2;13(1):120-127. doi: 10.1080/21645515.2016.1225639. Epub 2016 Sep 15. PubMed 27629913 ↗

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Feb 2013, 10 months.

Results were first posted in Jan 2019, 5 years 11 months after primary completion. A results delay was requested in Apr 2013.

Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 10 months is below that.

Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
May 16, 2011
StartActual
Apr 16, 2012
Primary completionActual
Feb 25, 2013
CompletionActual
Feb 25, 2013
Results delay requested
Apr 18, 2013
Results first posted
Jan 25, 2019
Last update
Jan 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01353703
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 16, 2011
Start date
Apr 16, 2012
Primary completion
Feb 25, 2013
Completion
Feb 25, 2013
Results posted
Jan 25, 2019
Last update
Jan 2, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion